BioStock: CombiGene comments the final preclinical steps
The gene therapy company CombiGene, which is developing a new treatment for drug-resistant focal epilepsy, is planning to focus on the final preclinical studies next year and then begin the first study in humans in 2022. BioStock turned to CEO Jan Nilsson for a status update and to talk about what remains to be done before the preclinical program can be terminated.
Read the full interview with CombiGene's CEO Jan Nilsson at biostock.se:
This is a pressrelease from BioStock - Connecting Innovation & Capital. https://www.biostock.se/